Te impact of human papillomavirus catch-up vaccination in Australia: Implications for introduction of multiple age cohort vaccination and postvaccination data interpretation

Journal of Infectious Diseases

Volumn 216, Issue 10, 2017, Pages 1205-1209

  Drolet, Mélanie ^a   Laprise, Jean François ^a   Brotherton, Julia M L ^b,c   Donovan, Basil ^d   Fairley, Christopher K ^e   Ali, Hammad ^d   Bénard, Élodie ^a   Martin, Dave ^a   Brisson, Marc ^a,f,g  

^a University Laval   (Canada)

^b VICTORIAN CYTOLOGY SERVICE   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e MONASH UNIVERSITY   (Australia)

^f UNIVERSITÉ LAVAL   (Canada)

^g IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Anogenital warts; Cervical cancers; Human papillomavirus; Mathematical modeling; Vaccination

Indexed keywords

WART VIRUS VACCINE;

ADULT; AUSTRALIA; COHORT ANALYSIS; CONDYLOMA ACUMINATUM; CONFERENCE PAPER; DRUG EFFICACY; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; MALE; MATHEMATICAL MODEL; NONHUMAN; PRIORITY JOURNAL; UTERINE CERVIX CANCER; VACCINATION; VIRUS TRANSMISSION; WART VIRUS; ADOLESCENT; CHILD; COMPLICATION; HEALTH SURVEY; IMMUNOLOGY; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTION; UTERINE CERVIX TUMOR; YOUNG ADULT;

ADOLESCENT; ADULT; AUSTRALIA; CHILD; CONDYLOMATA ACUMINATA; FEMALE; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; POPULATION SURVEILLANCE; UTERINE CERVICAL NEOPLASMS; VACCINATION; YOUNG ADULT;

EID: 85039848392     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jix476     Document Type: Conference Paper

References (15)

1. World Health Organization. Electronic address swi. Human papillomavirus vaccines: WHO position paper, May 2017-Recommendations. Vaccine 2017; 35: 5753-5. pii: S0264-410X(17)30728-4.
2. Bruni L, Diaz M, Barrionuevo-Rosas L, et al. Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis. Lancet Glob Health 2016; 4:e453-63.
3. Australian Government Departement of Health. Immunise Australia Progam. Human Papillomavirus (HPV). Available at: http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/immunise-hpv. Accessed 15 June 2017.
4. Drolet M, Bénard É, Boily MC, et al. Population-level impact and herd efects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis 2015; 15:565-80.
5. Van de Velde N, Boily MC, Drolet M, et al. Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model-based analysis. J Natl Cancer Inst 2012; 104:1712-23.
6. Malagón T, Drolet M, Boily MC, et al. Cross-protective ef-cacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012; 12:781-9.
7. Dobson SR, McNeil S, Dionne M, et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA 2013; 309:1793-802.
8. National HPV vaccination program register. HPV vaccination coverage data. Available at: http://www.hpvregister.org. au/. Accessed 3 April 2017.
9. Anic GM, Lee JH, Stockwell H, et al. Incidence and human papillomavirus (HPV) type distribution of genital warts in a multinational cohort of men: the HPV in men study. J Infect Dis 2011; 204:1886-92.
10. Winer RL, Kiviat NB, Hughes JP, et al. Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis 2005; 191:731-8.
11. Chaiyakunapruk N, Ng S. Human papillomavirus (HPV) vaccination: An updated systematic review of cost-efec-tiveness analyses. Summary of evidence. Background document for the 2016 SAGE meeting. Available at: http://www. who.int/immunization/sage/meetings/2016/october/06- Cost-efectiveness-analyses-of-HPV-immunization-pro-grammes.pdf?ua=1. Accessed 15 June 2017.
12. Wellings K, Collumbien M, Slaymaker E, et al. Sexual behaviour in context: a global perspective. Lancet 2006; 368:1706-28.
13. Guerra FM, Rosella LC, Dunn S, et al. Early impact of Ontario's human papillomavirus (HPV) vaccination program on anogenital warts (AGWs): a population-based assessment. Vaccine 2016; 34:4678-83.
14. Baandrup L, Blomberg M, Dehlendorf C, et al. Signifcant decrease in the incidence of genital warts in young Danish women after implementation of a national human papilloma-virus vaccination program. Sex Transm Dis 2013; 40:130-5.
15. Flagg E W, Schwartz R, Weinstock H. Prevalence of ano-genital warts among participants in private health plans in the United States, 2003-2010: potential impact of human papillomavirus vaccination. Am J Public Health 2013; 103:1428-35.